Raras
Buscar doenças, sintomas, genes...
Distrofia dos cones progressiva
ORPHA:1871CID-10 · H35.5CID-11 · 9B70DOENÇA RARA

Uma condição genética dos olhos que causa a perda das células cones. Essas células, que são sensíveis à luz, são responsáveis tanto pela visão central quanto pela capacidade de enxergar as cores.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma condição genética dos olhos que causa a perda das células cones. Essas células, que são sensíveis à luz, são responsáveis tanto pela visão central quanto pela capacidade de enxergar as cores.

Pesquisas ativas
4 ensaios
76 total registrados no ClinicalTrials.gov
Publicações científicas
65 artigos
Último publicado: 2025

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: H35.5
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
17 sintomas
💪
Músculos
1 sintomas

+ 6 sintomas em outras categorias

Características mais comuns

90%prev.
Defeito da visão de cores
Muito frequente (99-80%)
90%prev.
Eletroretinograma anormal
Muito frequente (99-80%)
90%prev.
Fotofobia
Muito frequente (99-80%)
90%prev.
Deficiência visual
Muito frequente (99-80%)
90%prev.
Anormalidade da pigmentação retiniana
Muito frequente (99-80%)
Perda visual progressiva
24sintomas
Muito frequente (5)
Sem dados (19)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 24 características clínicas mais associadas, ordenadas por frequência.

Defeito da visão de coresColor vision defect
Muito frequente (99-80%)90%
Eletroretinograma anormalAbnormal electroretinogram
Muito frequente (99-80%)90%
FotofobiaPhotophobia
Muito frequente (99-80%)90%
Deficiência visualVisual impairment
Muito frequente (99-80%)90%
Anormalidade da pigmentação retinianaAbnormality of retinal pigmentation
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico65PubMed
Últimos 10 anos7publicações
Pico20172 papers
Linha do tempo
2025Hoje · 2026🧪 2000Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

PDE6CCone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Disease-causing germline mutation(s) inTolerante
FUNÇÃO

As cone-specific cGMP phosphodiesterase, it plays an essential role in light detection and cone phototransduction by rapidly decreasing intracellular levels of cGMP

LOCALIZAÇÃO

Cell membrane

MECANISMO DE DOENÇA

Cone dystrophy 4

An early-onset cone dystrophy. Cone dystrophies are retinal dystrophies characterized by progressive degeneration of the cone photoreceptors with preservation of rod function, as indicated by electroretinogram. However, some rod involvement may be present in some cone dystrophies, particularly at late stage. Affected individuals suffer from photophobia, loss of visual acuity, color vision and central visual field. Another sign is the absence of macular lesions for many years. Cone dystrophies are distinguished from the cone-rod dystrophies in which some loss of peripheral vision also occurs.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cérebro - Hemisfério cerebelar
2.0 TPM
Cerebelo
1.8 TPM
Cervix Ectocervix
1.1 TPM
Nervo tibial
1.1 TPM
Cervix Endocervix
1.0 TPM
OUTRAS DOENÇAS (3)
cone dystrophy 4achromatopsiacone dystrophy
HGNC:8787UniProt:P51160
CNGB3Cyclic nucleotide-gated channel beta-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Pore-forming subunit of the cone cyclic nucleotide-gated channel. Mediates cone photoresponses at bright light converting transient changes in intracellular cGMP levels into electrical signals. In the dark, cGMP levels are high and keep the channel open enabling a steady inward current carried by Na(+) and Ca(2+) ions that leads to membrane depolarization and neurotransmitter release from synaptic terminals. Upon photon absorption cGMP levels decline leading to channel closure and membrane hyper

LOCALIZAÇÃO

Cell membrane

MECANISMO DE DOENÇA

Stargardt disease 1

An autosomal recessive form of Stargardt disease, a retinal degenerative disease characterized by macular dystrophy, progressive bilateral atrophy of the foveal retinal pigment epithelium, and accumulation of fluorescent flecks around the macula and/or in the central and near-peripheral areas of the retina. STGD1 patients typically lose central vision in their first or second decade of life.

OUTRAS DOENÇAS (4)
achromatopsia 3achromatopsiaStargardt diseasecone dystrophy
HGNC:2153UniProt:Q9NQW8
GNAT2Guanine nucleotide-binding protein G(t) subunit alpha-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Transducin is an amplifier and one of the transducers of a visual impulse that performs the coupling between rhodopsin and cGMP-phosphodiesterase

LOCALIZAÇÃO

Cell projection, cilium, photoreceptor outer segmentPhotoreceptor inner segment

VIAS BIOLÓGICAS (2)
Ca2+ pathwayG alpha (i) signalling events
MECANISMO DE DOENÇA

Achromatopsia 4

An ocular stationary disorder due to the absence of functioning cone photoreceptors in the retina. It is characterized by total colorblindness, low visual acuity, photophobia and nystagmus.

OUTRAS DOENÇAS (3)
achromatopsia 4cone dystrophyachromatopsia
HGNC:4394UniProt:P19087
GUCA1AGuanylyl cyclase-activating protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stimulates retinal guanylyl cyclase when free calcium ions concentration is low and inhibits guanylyl cyclase when free calcium ions concentration is elevated (PubMed:18706439, PubMed:19459154, PubMed:30184081, PubMed:30622141). This Ca(2+)-sensitive regulation of retinal guanylyl cyclase is a key event in recovery of the dark state of rod photoreceptors following light exposure (By similarity). May be involved in cone photoreceptor light response and recovery of response in bright light (By sim

LOCALIZAÇÃO

MembranePhotoreceptor inner segmentCell projection, cilium, photoreceptor outer segment

VIAS BIOLÓGICAS (1)
Inactivation, recovery and regulation of the phototransduction cascade
MECANISMO DE DOENÇA

Cone dystrophy 3

An autosomal dominant cone dystrophy. Cone dystrophies are retinal dystrophies characterized by progressive degeneration of the cone photoreceptors with preservation of rod function, as indicated by electroretinogram. However, some rod involvement may be present in some cone dystrophies, particularly at late stage. Affected individuals suffer from photophobia, loss of visual acuity, color vision and central visual field. Another sign is the absence of macular lesions for many years. Cone dystrophies are distinguished from the cone-rod dystrophies in which some loss of peripheral vision also occurs.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
52.1 TPM
Brain Nucleus accumbens basal ganglia
18.0 TPM
Hipotálamo
8.6 TPM
Brain Caudate basal ganglia
7.1 TPM
Brain Putamen basal ganglia
5.5 TPM
OUTRAS DOENÇAS (4)
cone dystrophy 3central areolar choroidal dystrophycone dystrophycone-rod dystrophy
HGNC:4678UniProt:P43080
KCNV2Potassium voltage-gated channel subfamily V member 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Potassium channel subunit. Modulates channel activity by shifting the threshold and the half-maximal activation to more negative values

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Voltage gated Potassium channels
MECANISMO DE DOENÇA

Cone dystrophy with supernormal rod responses

An autosomal recessive ocular disorder characterized by macular dysfunction, reduced and delayed cone responses, and supernormal and delayed rod responses. The onset of symptoms is in the first and second decades of life, and patients have reduced central vision, marked photophobia, reduced color discrimination predominantly along the red-green axes while tritan color vision is relatively well preserved. Nyctalopia is a later feature of the disorder.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
11.6 TPM
Cerebelo
0.9 TPM
Cérebro - Hemisfério cerebelar
0.8 TPM
Ovário
0.5 TPM
Nervo tibial
0.3 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
cone dystrophy with supernormal rod response
HGNC:19698UniProt:Q8TDN2
CACNA2D4Voltage-dependent calcium channel subunit alpha-2/delta-4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel

LOCALIZAÇÃO

Membrane

MECANISMO DE DOENÇA

Retinal cone dystrophy 4

Characterized by minimal symptoms except for slowly progressive reduction in visual acuity.

OUTRAS DOENÇAS (2)
retinal cone dystrophy 4cone-rod dystrophy
HGNC:20202UniProt:Q7Z3S7

Variantes genéticas (ClinVar)

466 variantes patogênicas registradas no ClinVar.

🧬 CACNA2D4: GRCh38/hg38 12p13.33-11.1(chr12:64621-34650483)x3 ()
🧬 CACNA2D4: GRCh38/hg38 12p13.33-q13.12(chr12:82453-49847230)x3 ()
🧬 CACNA2D4: GRCh37/hg19 12p13.33-13.2(chr12:173787-11553849)x3 ()
🧬 CACNA2D4: GRCh37/hg19 12p13.33-11.1(chr12:173787-34835837)x3 ()
🧬 CACNA2D4: NC_000012.11:g.(1920890_1949904)_(1984504_1987480)del ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 13 variantes classificadas pelo ClinVar.

10
3
Patogênica (76.9%)
Benigna (23.1%)
VARIANTES MAIS SIGNIFICATIVAS
PDE6B: NM_000283.4(PDE6B):c.1670A>G (p.His557Arg) [Likely pathogenic]
PCDH15: NM_033056.4(PCDH15):c.5847_5848del (p.His1949fs) [Likely pathogenic]
KCNV2: NM_133497.4(KCNV2):c.357dup (p.Lys120fs) [Pathogenic; drug response]
MKKS: NM_170784.3(MKKS):c.1239_1242dup (p.Thr415Ter) [Pathogenic]
CACNA1F: NM_001256789.3(CACNA1F):c.3853C>T (p.Arg1285Cys) [Pathogenic/Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 21
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia dos cones progressiva

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

76 ensaios clínicos encontrados, 4 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
7 papers (10 anos)
#1

Progressive Cone Dystrophy and Cone-Rod Dystrophy.

Advances in experimental medicine and biology2025

A heterogenous group of diseases, progressive cone dystrophy usually begins in the mid-teenage years or later in life. The estimated prevalence is 1 in 30,000-40,000 individuals. Patients usually present with decreased central vision and a color vision deficit; the visual loss is progressive and often accompanied by day blindness (hemeralopia) and light intolerance (photophobia). Over time, affected individuals develop night blindness and loss of peripheral field. Visual acuity deteriorates to 20/200 or even counting fingers. There is some association between X-linked cone-rod dystrophy (CORD) and high myopia.

#2

Promotion of endoplasmic reticulum retrotranslocation by overexpression of E3 ubiquitin-protein ligase synoviolin 1 reduces endoplasmic reticulum stress and preserves cone photoreceptors in cyclic nucleotide-gated channel deficiency.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology2024 Sep 15

Cone photoreceptor cyclic nucleotide-gated (CNG) channels play an essential role in phototransduction and cellular Ca2+ homeostasis. Mutations in genes encoding the channel subunits CNGA3 and CNGB3 are associated with achromatopsia, progressive cone dystrophy, and early-onset macular degeneration. Cone loss in patients with achromatopsia and cone dystrophy associated with CNG channel mutations has been documented by optical coherence tomography and in mouse models of CNG channel deficiency. Cone death in CNG channel-deficient retinas involves endoplasmic reticulum (ER) stress-associated apoptosis, dysregulation of cellular/ER Ca2+ homeostasis, impaired protein folding/processing, and impaired ER-associated degradation (ERAD). The E3 ubiquitin-protein ligase synoviolin 1 (SYVN1) is the primary component of the SYVN1/SEL1L ER retrotranslocon responsible for ERAD. Previous studies have shown that manipulations that protect cones and reduce ER stress/cone death in CNG channel deficiency, such as increasing ER Ca2+ preservation or treatment with an ER chaperone, increase the expression of SYVN1 and other components of the ER retrotranslocon. The present work investigated the effects of SYVN1 overexpression. Intraocular injection of AAV5-IRBP/GNAT2-Syvn1 resulted in overexpression of SYVN1 in cones of CNG channel-deficient mice. Following treatment, cone density in Cnga3-/- mice was significantly increased, compared with untreated controls, outer segment localization of cone opsin was improved, and ER stress/apoptotic cell death was reduced. Overexpression of SYVN1 also led to increased expression levels of the retrotranslocon components, degradation in ER protein 1 (DERL1), ERAD E3 ligase adaptor subunit (SEL1L), and homocysteine inducible ER protein with ubiquitin-like domain 1 (HERPUD1). Moreover, overexpression of SYVN1 likely enhanced protein ubiquitination/proteasome degradation in CNG channel-deficient retinas. This study demonstrates the role of SYVN1/ERAD in cone preservation in CNG channel deficiency and supports the strategy of promoting ERAD for cone protection.

#3

A duplication on chromosome 16q12 affecting the IRXB gene cluster is associated with autosomal dominant cone dystrophy with early tritanopic color vision defect.

Human molecular genetics2021 Jun 17

Cone dystrophies are a rare subgroup of inherited retinal dystrophies and hallmarked by color vision defects, low or decreasing visual acuity and central vision loss, nystagmus and photophobia. Applying genome-wide linkage analysis and array comparative genome hybridization, we identified a locus for autosomal dominant cone dystrophy on chromosome 16q12 in four independent multigeneration families. The locus is defined by duplications of variable size with a smallest region of overlap of 608 kb affecting the IRXB gene cluster and encompasses the genes IRX5 and IRX6. IRX5 and IRX6 belong to the Iroquois (Iro) protein family of homeodomain-containing transcription factors involved in patterning and regionalization of embryonic tissue in vertebrates, including the eye and the retina. All patients presented with a unique progressive cone dystrophy phenotype hallmarked by early tritanopic color vision defects. We propose that the disease underlies a misregulation of the IRXB gene cluster on chromosome 16q12 and demonstrate that overexpression of Irx5a and Irx6a, the two orthologous genes in zebrafish, results in visual impairment in 5-day-old zebrafish larvae.

#4

Progressive Cone Dystrophy and Cone-Rod Dystrophy (XL, AD, and AR).

Advances in experimental medicine and biology2018

A heterogenous group of diseases, progressive cone dystrophy usually begins in the mid-teenage years or later in life. The estimated prevalence is 1 in 30,000-40,000 individuals. Patients usually present with decreased central vision and a color vision deficit; the visual loss is progressive and often accompanied by day blindness (hemeralopia) and light intolerance (photophobia). Over time, affected individuals develop night blindness and loss of peripheral field. Visual acuity deteriorates to 20/200 or even counting fingers. There is some association between X-linked cone-rod dystrophy (CORD) and high myopia.

#5

Accessory heterozygous mutations in cone photoreceptor CNGA3 exacerbate CNG channel-associated retinopathy.

The Journal of clinical investigation2018 Dec 03

Mutations in CNGA3 and CNGB3, the genes encoding the subunits of the tetrameric cone photoreceptor cyclic nucleotide-gated ion channel, cause achromatopsia, a congenital retinal disorder characterized by loss of cone function. However, a small number of patients carrying the CNGB3/c.1208G>A;p.R403Q mutation present with a variable retinal phenotype ranging from complete and incomplete achromatopsia to moderate cone dysfunction or progressive cone dystrophy. By exploring a large patient cohort and published cases, we identified 16 unrelated individuals who were homozygous or (compound-)heterozygous for the CNGB3/c.1208G>A;p.R403Q mutation. In-depth genetic and clinical analysis revealed a co-occurrence of a mutant CNGA3 allele in a high proportion of these patients (10 of 16), likely contributing to the disease phenotype. To verify these findings, we generated a Cngb3R403Q/R403Q mouse model, which was crossbred with Cnga3-deficient (Cnga3-/-) mice to obtain triallelic Cnga3+/- Cngb3R403Q/R403Q mutants. As in human subjects, there was a striking genotype-phenotype correlation, since the presence of 1 Cnga3-null allele exacerbated the cone dystrophy phenotype in Cngb3R403Q/R403Q mice. These findings strongly suggest a digenic and triallelic inheritance pattern in a subset of patients with achromatopsia/severe cone dystrophy linked to the CNGB3/p.R403Q mutation, with important implications for diagnosis, prognosis, and genetic counseling.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia dos cones progressiva.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia dos cones progressiva

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Progressive Cone Dystrophy and Cone-Rod Dystrophy.
    Advances in experimental medicine and biology· 2025· PMID 40736814mais citado
  2. Promotion of endoplasmic reticulum retrotranslocation by overexpression of E3 ubiquitin-protein ligase synoviolin 1 reduces endoplasmic reticulum stress and preserves cone photoreceptors in cyclic nucleotide-gated channel deficiency.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology· 2024· PMID 39215566mais citado
  3. A duplication on chromosome 16q12 affecting the IRXB gene cluster is associated with autosomal dominant cone dystrophy with early tritanopic color vision defect.
    Human molecular genetics· 2021· PMID 33891002mais citado
  4. Progressive Cone Dystrophy and Cone-Rod Dystrophy (XL, AD, and AR).
    Advances in experimental medicine and biology· 2018· PMID 30578485mais citado
  5. Accessory heterozygous mutations in cone photoreceptor CNGA3 exacerbate CNG channel-associated retinopathy.
    The Journal of clinical investigation· 2018· PMID 30418171mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:1871(Orphanet)
  2. MONDO:0000455(MONDO)
  3. GARD:11897(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q32145951(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distrofia dos cones progressiva
Compêndio · Raras BR

Distrofia dos cones progressiva

ORPHA:1871 · MONDO:0000455
Prevalência
Unknown
Herança
Autosomal dominant, Autosomal recessive
CID-10
H35.5 · Distrofias hereditárias da retina
CID-11
Ensaios
4 ativos
Início
Adult
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0271092
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades